Oxygenta Pharmaceutical Limited

SSORGS

INE102E01018

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-07-16 am EDT			5-day change	1st Jan Change
32.14 ^INR	+5.00%		-2.52%	+3.15%

May. 30	Oxygenta Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
May. 21	Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding	CI

S.S. Organics Limited Appoints Pushapalatha Vustala as Additional Director (Non Executive Independent) of the Company

March 23, 2020 at 08:07 am EDT

The Board of Directors of S.S. Organics Limited has appointed Mrs. Pushapalatha Vustala as Additional Director (Non Executive Independent) of the Company, effective March 23, 2020, at the Board of Directors Meeting held on March 23, 2020.

Latest news about Oxygenta Pharmaceutical Limited

Oxygenta Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 30	CI
Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding	May. 20	CI
Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in funding	Apr. 07	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance Officer	23-10-11	CI
Oxygenta Pharmaceutical Limited Announces Board Appointments	23-10-01	CI
Oxygenta Pharmaceutical Limited Approves Board Changes	23-09-04	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance Officer	23-07-01	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Sunil Vishram Chawda, Manoj Sunil Chawda, Aakanksha M. Chawda and Raghavender Rao Kanuganti made an offer to acquire a 26% stake in Oxygenta Pharmaceutical Limited for approximately INR 130 million.	23-02-26	CI
Oxygenta Pharmaceutical Limited announced a financing transaction	23-02-26	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-12	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
SS Organics Adopts New Name	22-02-11	MT
S.S. Organics Ltd. has Changed its Name to Oxygenta Pharmaceutical Limited	22-02-10	CI
S.S. Organics Limited Announces Resignation of Directors	21-12-07	CI
S.S. Organics Limited Announces Resignations of Directors	21-12-07	CI
S.S. Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-15	CI
S.S. Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-12	CI
S.S. Organics Limited announced that it has received INR 40 million in funding	21-08-11	CI
S.S. Organics Limited Announces Appointment of Company Secretary and Compliance Officer	21-07-01	CI

Chart Oxygenta Pharmaceutical Limited

Duration

Period

More charts

Company Profile

Oxygenta Pharmaceutical Limited is an India-based company, which is primarily engaged in the manufacturing of bulk drugs and active pharmaceutical ingredients (API). The Company is also engaged in the business of manufacturing all classes and kinds of drugs, including pharmaceutical preparation, and organic fine chemicals. Its APIâs products include pantoprazole sodium, vildagliptin, telmisartan, lacosamide, and sertraline hydrochloride. The Companyâs chemical products include 3-Amino-1-adamantanol, (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile, 2-N-Propyl-4-methyl-6-(1-methyl benzimidazole-2-yl) benzimidazole, Isobutyramide, 4-Aminobenzonitrile, and others. The Company has its manufacturing facilities situated at Sadasivapet Mandal, Sangareddy District, Telangana State.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OXYGENTA PHARMACEUTICAL LIMITED	+3.15%	13M
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B